Squarepoint
VRTX icon

Squarepoint’s Vertex Pharmaceuticals VRTX Stock Holding History

Squarepoint’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63M Buy
5,300
+200
+4% +$88.6K ﹤0.01% 2123
2026
Q1 		$2.28M Sell
5,100
-500
-9% -$233K ﹤0.01% 2087
2025
Q4 		$2.54M Sell
5,600
-13,900
-71% -$5.99M ﹤0.01% 1895
2025
Q3 		$7.64M Buy
19,500
+8,200
+73% +$3.43M 0.01% 1217
2025
Q2 		$5.03M Buy
11,300
+4,200
+59% +$1.94M 0.01% 1461
2025
Q1 		$3.44M Buy
7,100
+800
+13% +$373K ﹤0.01% 1683
2024
Q4 		$2.54M Sell
6,300
-4,700
-43% -$2.18M ﹤0.01% 2211
2024
Q3 		$5.12M Sell
11,000
-9,700
-47% -$4.66M 0.01% 1404
2024
Q2 		$9.7M Buy
20,700
+19,600
+1,782% +$8.51M 0.02% 964
2024
Q1 		$460K Buy
+1,100
New +$465K ﹤0.01% 3104
2023
Q3 		– Sell
-1,400
Closed -$493K – 4294
2023
Q2 		$493K Buy
1,400
+300
+27% +$101K ﹤0.01% 2628
2023
Q1 		$347K Buy
+1,100
New +$330K ﹤0.01% 2494
2022
Q4 		– Sell
-800
Closed -$232K – 3639
2022
Q3 		$232K Sell
800
-5,800
-88% -$1.67M ﹤0.01% 2623
2022
Q2 		$1.86M Buy
+6,600
New +$1.77M 0.01% 1240

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Squarepoint's VRTX Position: Q2 2026 in Review

Squarepoint increased its Vertex Pharmaceuticals (VRTX) stake by 78% in Q2 2026, buying an estimated $2.34M and bringing the position to 12,031 shares worth $5.98M. The position accounts for 0.01% of the portfolio, ranked #1455.

Squarepoint first reported a position in VRTX in Q2 2015 and has held it in 37 quarters since. The position peaked at $238M in Q3 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Squarepoint held 12,031 shares of Vertex Pharmaceuticals worth $5.98M as of Q2 2026.
  • Squarepoint bought 5,279 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.34M.
  • Vertex Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1455 holding.
  • Squarepoint first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 37 quarters since.
  • Squarepoint's Vertex Pharmaceuticals position peaked at $238M in Q3 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.